Biogen Inc
NASDAQ: BIIB
$199.36
-$2.08 (-1.0%)
Closing Price on September 20, 2024
BIIB Articles
After largely shying away in the previous period, short sellers returned to many of the leading biotech and emerging pharmaceutical stocks in early February. The largest upswings happened to BioMarin...
Published:
Biogen Idec has announced that Chairman William D. Young will retire from the its board of directors and will be replaced by Stelios Papadopoulos. The latter is a former investment banker...
Published:
The equity team at Jefferies has pulled their best ideas for clients to review while the market is mired in a sell-off. These focus stocks to buy represent the best value the firm has been able to...
Published:
Biogen Idec surprised investors Wednesday with weaker-than-expected guidance for 2014 earnings. Amgen beat estimates late Tuesday. Celgene and Gilead Sciences report earnings on Thursday.
Published:
Frank Golhen, via Wikimedia CommonsMost of the firms that we cover on Wall Street have presented their high conviction stock picks for 2014. The analysts at Credit Suisse have taken a little bit...
Published:
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Monday, January 27, 2014. They include Cisco Systems, Lululemon Athletica, Nokia, Peabody Energy...
Published:
Here are some of the top biotech names to buy at Cowen. They presented such an extensive list that we focused on the quality large cap names and the stocks with the highest upside to their target...
Published:
In a new research report, the investment strategy team at Credit Suisse is recommending investors look to move out of the deep value stocks that have been so successful and consider stocks in the...
Published:
Last Updated:
As 2013 begins to wind down, 24/7 Wall St. has started to scan our coverage of Wall Street firms for ideas that have truly big upside for next year. After such an impressive rally for 2013 it remains...
Published:
Last Updated:
ThinkstockCredit Suisse is out and pounding the table that biotechnology cannot be ignored in 2014. Biotech has been the top-performing sector for the past three years, with year-to-date performance...
Published:
ThinkstockThe UBS proprietary institutional flow data indicates that hedge funds are increasing exposure to financials and decreasing exposure to health care. Given that health care has outperformed...
Published:
courtesy of AOL, IncHeading into the fourth quarter of this year, investors who have been long the stock market are poised for the best gains since the market exploded off the lows in 2009. While the...
Published:
ThinkstockThe world of biotechnology investing is a constantly evolving and changing one. While disease for the most part does not change all that much, the manner in which it can be treated does....
Published:
Jon OggInvestors and traders alike are looking for ideas and recommendations now that the government shutdown is here and with a debt ceiling debate ahead. Each morning 24/7 Wall St. reviews dozens...
Published:
Investors and traders are worried about an end to quantitative easing, yet stocks are rallying hard on fundamentals. This puts these same investors in a spot where they have to wonder which stocks to...
Published:
Last Updated: